Neumann Capital Management LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,259 shares of the biopharmaceutical company’s stock after selling 2,920 shares during the period. Gilead Sciences makes up 2.9% of Neumann Capital Management LLC’s portfolio, making the stock its 11th biggest position. Neumann Capital Management LLC’s holdings in Gilead Sciences were worth $4,548,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in GILD. Parnassus Investments CA increased its position in shares of Gilead Sciences by 37.4% during the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after purchasing an additional 4,556,901 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Gilead Sciences by 9.8% in the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after purchasing an additional 2,727,063 shares during the period. Pioneer Investment Management Inc. boosted its stake in Gilead Sciences by 84.0% in the 2nd quarter. Pioneer Investment Management Inc. now owns 3,493,148 shares of the biopharmaceutical company’s stock valued at $247,245,000 after purchasing an additional 1,595,085 shares during the period. Harbour Capital Advisors LLC boosted its stake in Gilead Sciences by 6,595.9% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,221,804 shares of the biopharmaceutical company’s stock valued at $17,262,000 after purchasing an additional 1,203,557 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its stake in Gilead Sciences by 75.0% in the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock valued at $173,148,000 after purchasing an additional 1,092,206 shares during the period. Institutional investors and hedge funds own 74.28% of the company’s stock.
In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total value of $1,138,200.00. Following the transaction, the executive vice president now directly owns 106,113 shares in the company, valued at approximately $8,051,854.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the transaction, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The disclosure for this sale can be found here. Insiders sold a total of 446,819 shares of company stock worth $36,338,919 over the last quarter. 1.30% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Gilead Sciences, Inc. (GILD) Stake Decreased by Neumann Capital Management LLC” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/10/30/gilead-sciences-inc-gild-stake-decreased-by-neumann-capital-management-llc.html.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 77.07 on Monday. The firm has a 50-day moving average of $82.01 and a 200 day moving average of $73.09. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a market cap of $100.65 billion, a P/E ratio of 8.37 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s revenue was down 13.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.75 EPS. Equities analysts expect that Gilead Sciences, Inc. will post $8.79 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.70%. Gilead Sciences’s payout ratio is 23.69%.
A number of research firms have recently weighed in on GILD. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research report on Thursday, August 31st. Deutsche Bank AG reissued a “buy” rating and set a $81.00 price target on shares of Gilead Sciences in a report on Thursday, August 31st. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target for the company in a report on Friday, October 13th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $85.00 target price (up previously from $79.00) on shares of Gilead Sciences in a report on Tuesday, August 29th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $85.68.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.